In a clinical study, at 26 weeks, more than half of the patients on HUMIRA saw significant symptom relief and many achieved remission. HUMIRA is a prescription medicine used to reduce signs and symptoms, and to achieve and maintain clinical remission in children 6 years of age and older with moderate to severe Crohn’s disease when certain other treatments have not worked well enough.
HUMIRA was first approved in the United States in 2002 as a biologic therapy and is currently approved to treat 9 different conditions. In 2014, HUMIRA received approval in the US to treat moderate to severe pediatric Crohn’s disease in children 6 years of age and older. Over 1.4 million patients have been prescribed HUMIRA worldwide across all approved indications.*
*As of July 2020.
Some people receiving TNF blockers including HUMIRA developed a rare type of cancer called hepatosplenic T-cell lymphoma (HSTCL), which often results in death. Most of these people were male teenagers or young men and also were being treated for inflammatory bowel disease with another medicine called Imuran®† (azathioprine) or Purinethol®† (6-mercaptopurine, 6–MP).
†All trademarks are the property of their respective companies.
HUMIRA is not right for everyone.
You may choose to have a HUMIRA Ambassador who is provided at no additional cost and offers one-to-one personalized support. Your Ambassador has received in-depth training on pediatric Crohn's disease and HUMIRA.
HUMIRA Ambassador services are available through HUMIRA Complete, an optional product support program offered to you by AbbVie that includes services such as injection training from a local registered nurse, financial assistance information, a HUMIRA Complete Co-pay Savings Card‡ (if eligible), and more. Your HUMIRA Ambassador can provide you and your child with one-to-one customized education and support as well as assist you with the other resources provided through HUMIRA Complete.
‡Terms and Conditions apply. This benefit covers HUMIRA® (adalimumab) alone or, for rheumatology patients, HUMIRA plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for HUMIRA who meet eligibility criteria. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the HUMIRA Complete Savings card and patient must call HUMIRA Complete at 1-800-4HUMIRA to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the HUMIRA Complete Program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out of pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html
Arava and Plaquenil are registered trademarks of their respective owners.